Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings Inc (NYSE American: SENS) is a pioneer in long-term implantable continuous glucose monitoring systems, transforming diabetes care through innovative medical technology. This news hub provides investors and healthcare professionals with timely updates on corporate developments, regulatory milestones, and clinical advancements.
Access official press releases covering financial results, product approvals, and strategic partnerships alongside analysis of key operational updates. Our curated news collection includes updates on Eversense CGM system enhancements, international market expansions, and clinical study outcomes.
Stay informed about critical developments including FDA submissions, European regulatory updates, and partnership announcements with global healthcare distributors. Bookmark this page for direct access to primary source materials essential for tracking Senseonics' progress in medical device innovation.
The Eversense® CGM System by Senseonics Holdings, Inc. has received an integrated CGM (iCGM) designation by the US FDA, allowing integration with insulin pumps for an automated insulin delivery system. Eversense is the first fully implantable device in its category with iCGM status, offering new interoperable CGM options. The partnership with Ascensia Diabetes Care aims to provide diabetes patients with advanced technology meeting high standards for accuracy, alert detection, and wear time.
FAQ
What is the current stock price of Senseonics (SENS)?
What is the market cap of Senseonics (SENS)?
